Drug Profile
Research programme: haematological disorder and eye disorder therapeutics - Q32 Bio
Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Homology Medicines
- Developer Novartis; Q32 Bio
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Eye disorders; Haemoglobinopathies
Most Recent Events
- 25 Mar 2024 Q32 Bio has merged with Homology Medicines to form Q32 Bio
- 27 Jul 2023 Research programme: adeno-associated virus based gene therapies - Homology Medicines/Novartis is available for licensing as of 27 Jul 2023. https://www.homologymedicines.com/pipeline/
- 27 Jul 2023 Discontinued - Preclinical for Eye disorders in Switzerland (Intravitreous)